The hearing process buys a few weeks but the path to compliance is blocked by the reverse-stock-split rule. Expect continued price pressure and potential transition to OTC markets. Short positioning has historically been profitable on this ticker; monitor for any capital raise attempts that could further dilute.
Price Chart
Executive Summary
ENvue Medical received a delisting notice from Nasdaq on July 10, 2026, because its closing bid price remained below $1.00 for 30 consecutive business days (May 26–July 8, 2026). The company is ineligible for the standard 180-day compliance period due to a 1-for-10 reverse stock split executed within the prior year. Management intends to request a hearing to appeal, which will stay suspension pending a panel decision, but there is no assurance of regaining compliance. For a $3M market-cap company with a recent dilutive S-3 filing, delisting risk is severe and likely to drive further downside.
Key Facts
- Nasdaq Staff Determination Letter received July 10, 2026; bid price <$1.00 for 30 consecutive business days
- Company not eligible for 180-day compliance period under Nasdaq Rule 5810(c)(3)(A)(iv) due to prior reverse stock split (1-for-10 on Aug 12, 2025)
- Company intends to request a hearing under Nasdaq Rule 5800 Series; timely request stays delisting pending panel decision
- Prior reverse split and recent S-3 filing (May 18, 2026) for resale of convertible shares highlight precarious financial position
Financial Impact
Loss of Nasdaq listing would severely reduce liquidity and institutional ownership, likely accelerating price decline for a $3M market-cap stock; no financial figures provided in this filing
Risk Factors
- Hearing panel may grant conditional continued listing with additional requirements
- Company could attempt another reverse split or capital raise to regain compliance, though prior split and S-3 limit options
- Delisting would trigger forced selling by institutional holders and index funds
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-032830 |
| Document: 0001493152-26-032830-index-headers.html | 0001493152-26-032830 |
| Document: 0001493152-26-032830-index.html | 0001493152-26-032830 |
| Document: 0001493152-26-032830.txt | 0001493152-26-032830 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | 8-K | $0.4900 | awaiting T+20 | — | $0.2500 (+48.98%) |
Sep 4, 2026 7w ago | EFFECT | $4.03 $1.03 | ▲ +74.44% | ▲ +75.04% | $0.2500 (+93.80%) |
Aug 31, 2026 7w ago | 8-K | $4.31 | awaiting T+20 | — | $0.2500 (−94.20%) |
Aug 12, 2026 10w ago | 8-K | $4.90 $3.57 | ▲ +27.08% | ▲ +25.19% | $0.2500 (+94.89%) |
Aug 10, 2026 10w ago | S-3 | $0.3982 $0.3033 | ▲ +23.82% | ▲ +22.76% | $0.2500 (+37.22%) |
Jul 10, 2026 15w ago | 8-K | $0.4578 $0.4140 | ▲ +9.57% | ▲ +12.75% | $0.2500 (+45.39%) |
Jun 3, 2026 20w ago | Press Release | $0.8600 $0.5200 | ▼ −39.53% | ▼ −38.53% | $0.2500 (−70.93%) |
May 29, 2026 21w ago | EFFECT | $0.9020 $0.5400 | ▲ +40.13% | ▲ +38.34% | $0.2500 (+72.28%) |
May 18, 2026 22w ago | S-3 | $0.9300 $0.7262 | ▲ +21.91% | ▲ +22.90% | $0.2500 (+73.12%) |
May 12, 2026 23w ago | Press Release | $1.24 $0.8530 | ▼ −31.21% | ▼ −29.48% | $0.2500 (−79.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers